Therapies are personalized and depend on several factors, including tumor subtype, tumor stage, genomic markers, patient age, general health, menopause status, and even the presence of mutations known as BRCA1 or BRCA2 [40,41]. The gene discussed is BRCA2; the disease is neoplasm.